Hepatitis C News and Research

Latest Hepatitis C News and Research

Many European hospitals fail to routinely test people at risk of HIV infection

A new study reveals that many European hospitals fail to routinely test people who may be at risk of an HIV-infection. If tests were more widely offered in the healthcare system, fewer HIV-patients would go unnoticed, especially in Northern Europe.

21 Nov 2015

New drug combination may reduce need for complex regimens to treat hepatitis C

The prognosis for people with hepatitis C has improved dramatically in the last few years, thanks to the introduction of direct-acting anti-viral medications, including Harvoni (the brand name for a combination of ledipasvir and sofosbuvir) and Viekira Pack (a mix of ombitasvir, paritaprevir, ritonavir and dasabuvir).

19 Nov 2015

Positive data from AbbVie's HCV clinical development program presented at The Liver Meeting of AASLD

AbbVie, a global biopharmaceutical company, today announced data from the SURVEYOR studies of its investigational HCV regimen, ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, that show high rates of sustained virologic response at 12 weeks post-treatment (SVR 12) in non-cirrhotic patients with chronic hepatitis C virus (HCV) infection.

17 Nov 2015

Nearly 50% of Medicaid patients infected with hepatitis C denied coverage for life-saving antiviral drugs

Nearly 50 percent of Medicaid patients infected with chronic hepatitis C whose doctors had prescribed newer, life-saving antiviral drugs were denied coverage to the therapies because they weren't considered "a medical necessity" or because the patients tested positive for alcohol/drugs, among other reasons, according to new Penn Medicine research.

17 Nov 2015

Study: Safe spaces may play critical role in community-based HIV prevention efforts

The creation and sustainment of "safe spaces" may play a critical role in community-based HIV prevention efforts by providing social support and reducing environmental barriers for vulnerable populations, a new study from an Oregon State University researcher has found.

17 Nov 2015

New US bipartisan study advocates promoting global health to advance wide range of American interests

A new US bipartisan study advocates promoting global health to both "do the right thing" and advance wide-ranging foreign policy interests.

17 Nov 2015

Study finds that living liver donors highly satisfied with donation process

A study of living liver donors found donors were highly satisfied with the donation process. Findings published in Liver Transplantation, a journal of the American Association for the Study of Liver Diseases, indicate most donors would donate again, independent of any complications from transplantation.

17 Nov 2015

New cancer control interventions may decrease cancer burden in low- and middle-income countries

In low-income and middle-income countries (LMICs), where 5.5 million of the world’s 8 million cancer deaths occur each year, most people with cancer have little or no access to treatment and many die in severe pain for lack of inexpensive opioid pain medicine.

17 Nov 2015

UC Irvine Health researchers develop one-step test to detect HCV infections

UC Irvine Health researchers have developed a cost-effective one-step test that screens, detects and confirms hepatitis C virus (HCV) infections. Dr. Ke-Qin Hu, director of hepatology services, will present findings at the Annual Meeting of American Association for the Study of Liver Disease in San Francisco, Nov. 14-16. Current blood-based HCV testing requires two steps and can be expensive, inconvenient and is not widely available or affordable globally.

15 Nov 2015

FixHepC Buyers Club exposes weakness in Australian healthcare, assists patients to import life saving medication

In one of the greatest advances in medicine in decades, Hepatitis C is now largely curable. Over 200,000 Australians suffer from Hepatitis C. However the US manufacturer, Gilead Sciences Inc is attempting to charge the PBS $84,000 for a 12 week course of medication that costs under $200 dollars to manufacture.

13 Nov 2015

Montefiore and Einstein researchers awarded $14 million PCORI grant for hepatitis C research

A research team at Montefiore Health System and Albert Einstein College of Medicine led by Alain Litwin, M.D., was awarded $14 million by the Patient-Centered Outcomes Research Institute (PCORI) to determine how best to treat hepatitis C among people who inject drugs (PWID), a group with a high rate of infection.

11 Nov 2015

ACR releases 2015 Guideline for Treatment of Rheumatoid Arthritis

The American College of Rheumatology (ACR) released its 2015 Guideline for the Treatment of Rheumatoid Arthritis (RA) during the 2015 ACR/ARHP Annual Meeting in San Francisco.

11 Nov 2015

New funding for Centenary's life saving research

The Centenary Institute has welcomed the Federal Government’s announcement of funding for 9 new and innovative medical research projects via the latest round of NHMRC grant rounds funding, officially confirmed today.

9 Nov 2015

Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene.

9 Nov 2015

MPP announces expansion of mandate to hepatitis C and TB medicines

The Medicines Patent Pool, the world's only voluntary licensing mechanism in public health, announced an expansion of its mandate today to hepatitis C and tuberculosis medicines. The UNITAID Executive Board, meeting November 4-5 in Geneva, approved the MPP's proposals to improve access to both life-saving direct acting antivirals (DAAs) to treat hepatitis C and new and re-purposed medicines for tuberculosis.

6 Nov 2015

Genvoya approved as complete regimen for HIV treatment

The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.

6 Nov 2015

Johnson & Johnson signs definitive agreement to purchase Novira Therapeutics

Johnson & Johnson today announced a definitive agreement to acquire Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection.

4 Nov 2015

Study provides novel insight into the evolution of hepatitis A virus and how it spreads to humans

Researchers at the University of North Carolina at Chapel Hill are part of an international team led by the University of Bonn, Germany, who have found a link between the origin of hepatitis A virus (HAV) and small mammals.

4 Nov 2015

HIV, Ebola appear to be of animal origin

The hepatitis A virus can trigger acute liver inflammation which generally has a mild course in small children but which can become dangerous in adults.

3 Nov 2015

New paper device could rapidly and inexpensively assess hepatitis B, male infertility

Scientists have developed a new paper device that analyzes DNA and could rapidly and inexpensively assess disparate conditions including hepatitis B and male infertility, which together affect millions of people around the world. The test, reported in the Journal of the American Chemical Society, could be of particular help diagnosing people in low-income areas.

29 Oct 2015

Hepatitis C News and Research

Latest Hepatitis C News and Research

Many European hospitals fail to routinely test people at risk of HIV infection

New drug combination may reduce need for complex regimens to treat hepatitis C

Positive data from AbbVie's HCV clinical development program presented at The Liver Meeting of AASLD

Nearly 50% of Medicaid patients infected with hepatitis C denied coverage for life-saving antiviral drugs

Study: Safe spaces may play critical role in community-based HIV prevention efforts

New US bipartisan study advocates promoting global health to advance wide range of American interests

Study finds that living liver donors highly satisfied with donation process

New cancer control interventions may decrease cancer burden in low- and middle-income countries

UC Irvine Health researchers develop one-step test to detect HCV infections

FixHepC Buyers Club exposes weakness in Australian healthcare, assists patients to import life saving medication

Montefiore and Einstein researchers awarded $14 million PCORI grant for hepatitis C research

ACR releases 2015 Guideline for Treatment of Rheumatoid Arthritis

New funding for Centenary's life saving research

Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

MPP announces expansion of mandate to hepatitis C and TB medicines

Genvoya approved as complete regimen for HIV treatment

Johnson & Johnson signs definitive agreement to purchase Novira Therapeutics

Study provides novel insight into the evolution of hepatitis A virus and how it spreads to humans

HIV, Ebola appear to be of animal origin

New paper device could rapidly and inexpensively assess hepatitis B, male infertility

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Hepatitis C News and Research

Latest Hepatitis C News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in